The worldwide prevalence of infection with human papillomavirus (HPV) in women without
cervical abnormalities is 11–12% with higher rates in sub-Saharan Africa (24%), Eastern …

Human Papillomavirus (HPV) research has been dominated by the study of a subset of
Alpha papillomaviruses that together cause almost 5% of human cancers worldwide, with …

Abstract Background Anogenital warts (AGWs) are a common, highly infectious disease
caused by the human papillomavirus (HPV), whose high recurrence rates contribute to direct …

The EUROGIN 2011 roadmap reviews the current burden of human papillomavirus (HPV)‐
related morbidity, as well as the evidence and potential practice recommendations …

This chapter reviews the current treatment of chronic and neoplastic human papillomavirus
(HPV)-associated conditions and the development of novel therapeutic approaches …

Background The role of human papillomavirus (HPV) in malignant and non-malignant
genital diseases in women is well known and the corresponding epidemiological burden …

Human papillomavirus (HPV) infection is a central and necessary, although not sufficient,
cause of cervical cancer. Besides HPV, the additional multiple risk factors related with the …

Introduction A second generation HPV vaccine has been developed for the prevention of
anogenital cancers and precancerous lesions of the cervix, vulva, vagina, anus and of …

Objectives To compare the effect and cost effectiveness of bivalent and quadrivalent human
papillomavirus (HPV) vaccination, taking into account differences in licensure indications …

Objectives To estimate the loss of quality of life and cost of treatment associated with genital
warts seen in sexual health clinics. Methods A cross-sectional questionnaire study and case …